WHAT IS CLAIMED IS:

1. The use of 17-β estradiol or a derivative thereof in the making of a medication, for *in-situ* administration in the lumen of a blood vessel having suffered vascular injury, at the injured site, to prevent vascular intima hyperplasia, or for improving vascular endothelium function, or both, in a patient.

2. An anti-restenotic composition for in-situ administration in the lumen of a blood vessel having suffered vascular injury, at the injured site, which comprises an effective amount of 17-β estradiol or a derivative thereof in a pharmaceutically acceptable carrier.

3. A device comprising 17-β estradiol or a derivative thereof for in-situ delivery of an anti-restenotic amount thereof to a vascular site having suffered vascular injury.

4. The use as defined in claim 1, or the composition as defined in claim 2, or the device of claim 3, wherein 17-β estradiol or a derivative thereof is present in a dose unit of 1 to 5000 µg/Kg of patient's body weight.

5. The use, as defined in claim 1, or the composition as defined in claim 2, or the device of claim 3, wherein 17-β estradiol or a derivative thereof is present in a dose unit of 10 to 50 µg/Kg Kg of patient's body weight.

6. The use as defined in claim 1, or the composition as defined in claim 2, or the device of claim 3, wherein 17-β estradiol or a

derivative thereof is present in a dose unit of 10 to 30 µg/Kg Kg of patient's body weight.

7. The use or the composition as defined in any one of claims 1, 2 and 4 to 6 wherein said pharmaceutically acceptable carrier comprises hydroxypropyl-beta-cyclodextrin (HPCD).

8. The use or the composition as defined in claim 7, wherein HPCD is present in a dose capable of solubilizing 17-beta estradiol or a derivative thereof.

9. The use or the composition as defined in Claim 6, where 17-beta-estradiol or a derivative thereof is admixed with a carrier comprising at least 0.63 mg hydroxypropyl-beta-cyclodextrin per kilogram of patient's body weight.